The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Pursue Excellence, driven by innovation, integrity and win-win cooperation
Beijing Increasepharm Corporation Limited is committed to extensive research and development of innovative drugs. Founded in 1999, Increasepharm has since established eight subsidiaries across China. We keep in step with the latest national technology development plan in the Greater Bay Area and expand the Group's overseas international R&D business. Increasepharm (HK) Limited was founded in 2018 to bridge the overall biotechnology development planning between Hong Kong and the Greater Bay Area.
Increasepharm HK strives to establish a research-based development centre within three years for innovative biosynthesis of drugs in addition to new formulations. With the overarching goal of focusing and relying on Increasepharm's core R&D platform based in China, we aim to expand the Group's related R&D services. Increasepharm HK closely cooperates with many local scientific research institutions and enterprises to not only carry out new drug, pharmacodynamic toxicology and clinical research, but also to provide international drug registration, training, testing and other services.